CD19-targeting CAR-T cell therapy has also achieved significant clinical responses in patients with chronic lymphocytic leukaemia (CLL) and non-Hodgkin’s lymphoma4–7. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.